Clinical Practice Recommendations on Genetic Testing of XXXX and @entity5058 Variants in @entity1229 Therapy.

@entity1 @entity548 @entity5058 @entity5062 @entity30883 @entity32602 @entity5060 @entity1229
OBJECTIVE: To systematically review evidence on genetic variants influencing outcomes during @entity1229 therapy and provide practice recommendations addressing the key questions: (1) Should genetic testing be performed in @entity1 with an indication for @entity1229 therapy to improve achievement of stable anticoagulation and reduce adverse effects? (2) Are there subgroups of @entity1 who may benefit more from genetic testing compared with others? (3) How should @entity1 with an indication for @entity1229 therapy be managed based on their genetic test results? METHODS: A systematic literature search was performed for @entity5058 and @entity5060 and their association with @entity1229 therapy. Evidence was critically appraised, and clinical practice recommendations were developed based on expert group consensus. RESULTS: Testing of @entity5058 ( @entity30883 ), @entity5060 *2, and @entity5060 *3 should be considered for all @entity1 , including pediatric @entity1 , within the first 2 weeks of therapy or after a @entity548 event. Testing for @entity5060 *5, *6, *8, or *11 and @entity5062 ( @entity32602 ) is currently not recommended. Testing should also be considered for all @entity1 who are at increased risk of @entity548 complications, who consistently show out-of-range international normalized ratios, or suffer adverse events while receiving @entity1229 . Genotyping results should be interpreted using a pharmacogenetic dosing algorithm to estimate the required dose. SIGNIFICANCE: This review provides the latest update on genetic markers for @entity1229 therapy, clinical practice recommendations as a basis for informed decision making regarding the use of genotype-guided dosing in @entity1 with an indication for @entity1229 therapy, and identifies knowledge gaps to guide future research.
